Navigation Links
Gentiva Reports Strong Second Quarter led by Home Health Segment
Date:7/31/2008

25% rise in net income to $19.7 million, or $0.68 per diluted share, versus $15.8 million, or $0.56 per diluted share, for the first half of 2007.

-- An 11% increase in EBITDA to $55.3 million versus $49.6 million in the prior-year period. Excluding charges for restructuring and integration costs, EBITDA for the period would have been $56.0 million, or $0.69 per diluted share, compared to $51.2 million and $0.59 per diluted share in the prior-year period.

Gentiva announced that it is raising its 2008 outlook for net revenues to a range of $1.32 billion to $1.35 billion, as compared to $1.28 billion to $1.32 billion, and now expects its diluted earnings per share to be between $1.36 and $1.43, up from the $1.32 to $1.40 range announced earlier this year. Projected earnings exclude special items and restructuring and integration costs.

Non-GAAP Financial Measures

The information provided in this press release includes certain non-GAAP financial measures as defined under Securities and Exchange Commission (SEC) rules. In accordance with SEC rules, the Company has provided, in the supplemental information and the footnotes to the tables, a reconciliation of those measures to the most directly comparable GAAP measures.

Conference Call and Web Cast Details

The Company will comment further on its second quarter results during its conference call and live web cast to be held Thursday, July 31, 2008, at 10:00 a.m. Eastern Time. To participate in the call from the United States, Canada or an international location, dial (973) 935-2408 and reference call #56178391. The web cast is an audio-only, one-way event. Web cast listeners who wish to ask questions must participate in the conference call. Log onto http://investors.gentiva.com/events.cfm to hear the web cast. This press release is accessible at htt
'/>"/>

SOURCE Gentiva Health Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports Second Quarter 2008 Financial Results
2. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
3. Neurocrine Biosciences Reports Second Quarter 2008 Results
4. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
5. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
6. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
8. Cepheid Reports Second Quarter Revenue of $42.1 Million
9. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
10. Lilly Reports Solid Second-Quarter Results
11. Sangamo BioSciences Reports Second Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...Nov. 19 Dr. Mate Hidvegi, inventor...to a press release issued on November 17 by Biroph...aking false and self-serving statements about its ...idvegi stated from his office in Budapest, Hungary...emar does not apply to AveULTRA, www.aveultra.co...
(Date:11/19/2009)...9 NeoStem, Inc. (NYSE Am...ollowing letter to its shareholders, discussing th...hina Biopharmaceuticals Holdings, Inc. (CHBP), an ... People,s Republic of China. The merger gives NeoS...maceutical Co. Ltd., CHBP,s primary operating subs...
(Date:11/19/2009)... and WALTHAM, Mass., Nov. 19 Arlin...s find that the leading driver of antibiotic selec...ectrum activity against gram-positive and gram-neg...hat can cause nosocomial pneumonia, surveyed Europ... agents that provide appropriate coverage against ...
(Date:11/19/2009)...9 /PRNewswire/ - Aegera Therapeutics Inc. announce...mized Phase 2B study of AEG35156, a targeted antis...iple oncology indications. ,, The study, entitl...X-Linked Inhibitor of Apoptosis (XIAP) Antisense A...bine and Idarubicin in AML Following Failure of a ...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
... May 11 Pharmasset, Inc. (Nasdaq: VRUS ), a cli...scovering, developing, and commercializing novel d... results and operational highlights for the fiscal...sults , , Revenues were $1.9 million during the ...ion for the quarter ended March 31, 2008 and refle...
...1, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: AR...t quarter ended March 31, 2009. , , Arena report...the first quarter of 2009 of $50.6 million, or $0....common stockholders in the first quarter of 2008 o...ing the positive lorcaserin BLOOM results was a si...
... joins the Digital Arts Alliance , , BATON ROUGE,...ed plans to support, for the second year in a row,...nsive Orientation for Students (BIOS) program with... class of Pearson Foundation Digital Arts Fellows ...es and pass them along to future program participa...
Other Biology Technology:Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 2Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 3
(Date:11/20/2009)... Using highly precise measurements of plasma lipop...ic resonance spectroscopy (NMR), researchers led b...nd Harvard Medical School in Boston, MA, the Frami... consortium in Stockholm, Sweden and Oxford, Engla...he whole genome among 17,296 women of European anc...
(Date:11/20/2009)... Researchers are invited to contribute their abstr...OF WCO ECCEO10), the largest global meeting devot...is research and patient care. The Congress will be...eginning today, abstracts can be submitted online ...sion deadline is February 4, 2010. , IOF and ESC...
(Date:11/20/2009)..., A key question in the origin of biological mol...ether billions of years ago from simple precursors...searchers in Italy have reconstructed one of the e...ains of RNA from individual subunits using nothing...t RNA was one of the first biological molecules pr...
Breaking Biology News(10 mins):Genetic analysis helps dissect molecular basis of cardiovascular disease 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3National Coalition of Front Line Skilled Nursing Clinicians 3A Bipartisan Momentum to Stop CMS Medicare Regulation Subsequent Funding Cuts Grows in 53116 1National Coalition of Front Line Skilled Nursing Clinicians 3A Bipartisan Momentum to Stop CMS Medicare Regulation Subsequent Funding Cuts Grows in 53116 2National Coalition of Front Line Skilled Nursing Clinicians 3A Bipartisan Momentum to Stop CMS Medicare Regulation Subsequent Funding Cuts Grows in 53116 3National Coalition of Front Line Skilled Nursing Clinicians 3A Bipartisan Momentum to Stop CMS Medicare Regulation Subsequent Funding Cuts Grows in 53116 4Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 13255 1Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 13255 2Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 13255 3Stryker Announces Election of New Director 53107 1Stryker Announces Election of New Director 53107 2
...uebec City, Canada - An international team of scie...iversity of Hull, Cardiff University) and Spain (D...pair of closely related species of East African ci...rising hundreds of species has puzzled evolutionar... gene adaptations which might explain why they do ...
...AINESVILLE, Fla. When the first four-legged animal...genetic recipe and simply extended the cooking tim... Wednesdays issue of the journal PLoS ONE. , Ev... billion years have the recipe for fingers in thei...hem. , While studying the mechanisms of developm...
...OSTONColon cancer patients who eat a diet high in ...erts a so-called Western diet may be increasing ...eport researchers at Dana-Farber Cancer Institute....he Journal of the American Medical Association, in...that has been treated with both surgery and chemot...
Other Biology News:Adaptation to parasites drive African fishes along different evolutionary paths 2Conquest of land began in shark genome 2Conquest of land began in shark genome 3'Western' diet linked to increased risk of colon cancer recurrence 2
CLEARMOUNT from Invitrogen
...Polyclonal Antibody Production Conjugated pepti...abbits ten-week protocol to produce antibodies in...00-120 ml antiserum) ELISA test until the titer r...eaches target titer Protein G purification Antib...
3' RACE Adapter Primer from Invitrogen
Normal Goat Serum from Calbiochem
Biology Products: